查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
精准医疗中的人工智慧 (AI) 市场：2023-2028 年预测
市场调查报告书
商品编码
1410106

精准医疗中的人工智慧 (AI) 市场：2023-2028 年预测

AI in Precision Medicine Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 149 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

2021年精准医疗市场人工智慧（AI）的市场规模为13.22亿美元，预计在预测期内复合年增长率为27.63%。

在精准医疗领域，人工智慧正成为一股变革力量，将人工智慧的潜力与医疗保健结合，彻底改变患者照护。利用人工智慧演算法和机器学习技术，可以研究海量的患者资料，如基因图谱、病历、生活方式讯息，使我们能够提供个人化、有针对性的治疗方案。随着医疗保健提供者和製药公司看到了改善患者治疗结果、提高诊断准确性和加快药物研发过程的潜力，精准医疗领域的人工智慧 (AI) 市场正在迅速扩大。Masu。人工智慧驱动的平台可以检测大资料集的模式和相关性，从而实现疾病风险预测和个人化治疗的创建。随着人工智慧的进步，它有望改变精准医疗的格局，提供新的技术来提供个人化的医疗干预，并彻底改变患者照护的未来。

资料分析和机器学习演算法的进步正在推动精准医疗领域人工智慧 (AI) 市场的成长。

资料分析和机器学习演算法的进步在人工智慧在精准医疗业务中的扩展中发挥关键作用。这些发展使医疗保健专业人员能够分析大型且复杂的资料集，提取有用的见解，并更有效地设计个人化治疗方法。机器学习演算法检测患者资料中的模式和联繫，以帮助疾病诊断、预后和治疗效果评估。这些演算法准确性和效率的提高将加速人工智慧 (AI) 在精准医疗中的应用，为医护人员提供强大的工具来提供有针对性的有效治疗，并改善患者的治疗效果。

精准医疗领域的人工智慧 (AI) 市场对个人化和标靶化治疗方法的需求不断增长。

对个人化和标靶治疗方案的日益增长的需求正在推动人工智慧在精准医疗行业的兴起。传统的医疗方法通常依赖笼统的治疗计划，可能没有考虑个别差异和特殊需求。但由于人工智慧的突破，医疗保健专业人员现在可以利用患者特定的资料来建立个人化治疗。为了提案个人化治疗方法，人工智慧系统可以分析遗传资讯、病历、生活方式和环境资料等各种因素。这种方法有可能提高治疗效果、减少副作用并改善患者的治疗结果。随着个人化医疗对于提供更准确、更有效的医疗保健治疗的重要性的认识，精准医疗领域对人工智慧的需求不断增加。

精准医疗市场中的人工智慧 (AI) 可改善患者的治疗效果和治疗效果。

改善患者治疗效果和治疗效果是精准医疗市场中人工智慧应用的关键驱动力。根据发表在 JAMA Network Open 上的一项研究，精准医疗中采用的人工智慧演算法已证明能够可靠地预测患者的结果和治疗效果。在临床决策流程中使用人工智慧可以将某些疾病的治疗效果提高30-50%。 《医学网路研究期刊》上发表的另一项研究发现，使用人工智慧的精准医疗可减少 14%的不利事件和 25% 的再入院率。这些结果证明了人工智慧在改善治疗方法、发现成功药物和节省医疗成本方面的潜力。透过利用人工智慧的分析能力和资料主导的洞察力，医疗保健专业人员可以做出更明智的决策，从而改善患者的治疗效果和治疗效果，并最终提高护理品质。

北美是精准医疗领域人工智慧 (AI) 的市场领导者。

北美已成为精准医疗市场人工智慧的市场领导者。该地区的主导地位有几个原因。首先，北美拥有强大的医疗基础设施和先进的技术创新，支援人工智慧（AI）在精准医疗中的应用。此外，北美拥有顶尖的製药和生物技术公司、研究机构和学术中心，有助于该公司的市场领导地位。该地区正大力投资人工智慧研发，推动精准医疗创新。此外，北美拥有有利的法律规范和支援政策，可以刺激人工智慧在医疗保健领域的应用。然而，有关精准医疗市场人工智慧（AI）关键领域的最新信息，请参阅最新的市场报告。

人工智慧与基因定序和精准医疗的结合扩大了精准医疗领域人工智慧（AI）的市场规模

在医疗健康领域，基因定序、精准医疗和人工智慧的整合已成为重要的成长因素。基因定序产生大量遗传资料，当使用人工智慧演算法进行分析时，可以发现与疾病相关的基因突变并提供个人化的治疗方案。使用人工智慧进行基因组分析已显示出可喜的结果，一些研究显示罕见疾病的诊断率为 30%。人工智慧系统还可以根据基因图谱预测药物反应，从而实现更量身定制和有效的治疗。人工智慧和基因定序的结合有可能改变精准医疗，根据个人的基因组成提供个人化治疗，改善患者的治疗结果和治疗效果。

主要进展

  • 2023 年7 月，人工智慧和精准医疗领域的先驱Tempos 与TScan Therapeutics 合作，TScan Therapeutics 是一家临床阶段的生物製药公司，专注于为癌症患者开发TCR 工程T 细胞疗法（TCR-T）。今天我们宣布了一项新的合作合作开发伴同性诊断 (CDx) 测试。该合作伙伴关係将支持 TScan 的 1 期固体癌临床试验筛检程序，使患者能够接受基于肿瘤抗原阳性和完整 HLA 表达的客製化 TCR-T 组合。
  • 2021 年 9 月 魁北克人工智慧研究所 (Mila) 今天宣布与人工智慧治疗领域的领导者 Deep Genomics 建立合作伙伴关係。该协议允许该公司加入 Mila 的网路并从该研究所的研究业务中受益。深度基因组学利用人工智慧和机器学习来编程和选择针对医疗需求未满足的遗传性疾病的突破性治疗方法。
  • 2023 年 6 月 Apptio Inc. 是财务和业务IT 管理及优化软体领域的先驱，今天被 IBM 在与 Vista Equity Partners 的最终交易中以 46 亿美元的价格收购。收购 Apptio 将加速 IBM 的 IT 自动化能力，并使管理人员能够从其技术投资中获得更大的商业价值。

公司产品

  • 基因组序列测定： Tempus 提供完整的基因序列测定服务，创建高品质的遗传资料，与临床资料结合，可以揭示疾病发展和治疗反应的见解。
  • 研究合作计画： 23andMe 与学术机构和製药公司合作，收集资料遗传和表型资料用于研究。透过使用人工智慧分析这个庞大的资料集，研究人员可以发现遗传见解并确定新的治疗标靶。
  • SOPHiA DDM 平台： SOPHiA GENETICS 提供了一个全面的人工智慧平台，该平台使用机器学习和复杂的演算法来分析和解释遗传资料。该平台有助于识别致病突变、预测治疗反应并指导个人化治疗决策。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 资讯来源
  • 研究设计

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场抑制因素
  • 波特五力分析
    • 供应商的议价能力
    • 买方议价能力
    • 新进入者的威胁
    • 替代品的威胁
    • 业内竞争对手之间的对抗关係
  • 产业价值链分析

第五章精准医疗中的人工智慧（AI）市场：依技术划分

  • 介绍
  • 机器学习
  • 自然语言处理（NLP）
  • 深度学习
  • 巨量资料分析
  • 其他的

第六章精准医疗中的人工智慧（AI）市场：依应用分类

  • 介绍
  • 药物研发发现与开发
  • 肿瘤学
  • 基因检测
  • 罕见疾病
  • 感染疾病
  • 其他的

第七章精准医疗中的人工智慧 (AI) 市场：按最终用户划分

  • 介绍
  • 製药和生物技术公司
  • 研究机构和学术中心
  • 医疗机构
  • 其他的

第八章精准医疗中的人工智慧（AI）市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 台湾
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 新兴企业和市场盈利
  • 合併、收购、协议和合作
  • 供应商竞赛矩阵

第十章 公司简介

  • IBM Corporation
  • Google LLC（Alphabet Inc.）
  • Microsoft Corporation
  • Amazon Web Services（AWS）
  • Intel Corporation
  • NVIDIA Corporation
  • Flatiron Health（Roche Holding AG）
  • Tempus Labs, Inc.
  • Foundation Medicine, Inc.（Roche Holding AG）
  • 2bPrecise LLC（Allscripts Healthcare Solutions, Inc.）
简介目录
Product Code: KSI061615751

AI in precision medicine market was valued at US$1.322 billion in 2021 and is expected to grow at a CAGR of 27.63% during the forecast period.

In the field of precision medicine, AI has emerged as a transformational force, merging the potential of artificial intelligence with healthcare to revolutionize patient care. The use of AI algorithms and machine learning techniques has allowed for the study of massive volumes of patient data, such as genetic profiles, medical records, and lifestyle information, to provide personalized and targeted treatment solutions. Artificial intelligence (AI) in precision medicine market is expanding rapidly as healthcare providers and pharmaceutical firms see its potential to improve patient outcomes, increase diagnosis accuracy, and expedite drug discovery processes. AI-powered platforms can detect patterns and correlations in large datasets, allowing for illness risk prediction and the creation of personalized therapies. As AI advances, it has enormous promise for changing the landscape of precision medicine, providing fresh techniques to deliver personalized healthcare interventions, and revolutionizing the future of patient care.

Advancements in Data Analytics and Machine Learning Algorithms bolsters AI in Precision Medicine Market Growth.

Data analytics and machine learning algorithms advancements have played a critical part in the expansion of AI in the precision medicine business. These developments have enabled healthcare practitioners to analyze massive and complicated datasets, extract useful insights, and design personalized treatment methods more efficiently. Machine learning algorithms detect patterns and connections in patient data, assisting in illness diagnosis, prognosis, and therapy response evaluation. These algorithms' enhanced accuracy and efficiency have accelerated the use of AI in precision medicine, providing healthcare practitioners with strong tools to perform targeted and effective therapies, thereby improving patient outcomes.

Rising Demand for Personalized and Targeted Treatment Approaches in AI in Precision Medicine Market.

The growing desire for personalized and targeted treatment options has aided AI's rise in the precision medicine business. Traditional healthcare approaches frequently rely on generalized treatment plans that may fail to account for individual differences and special demands. However, thanks to breakthroughs in artificial intelligence, healthcare professionals may now use patient-specific data to build personalized therapies. To develop personalized treatment recommendations, AI systems may analyze a variety of elements such as genetic information, medical history, lifestyle, and environmental data. This method has the potential to improve therapeutic efficacy, reduce side effects, and improve patient outcomes. The growing appreciation for the significance of personalized medicine in providing more precise and effective healthcare treatments has increased the demand for AI in the field of precision medicine.

Improving Patient Outcomes and Treatment Efficacy in AI in Precision Medicine Market.

Improving patient outcomes and treatment efficacy is a key driver in the precision medicine market's use of AI. AI algorithms employed in precision medicine have shown the capacity to reliably predict patient outcomes and treatment responses, according to a study published in JAMA Network Open. The use of AI in clinical decision-making processes has resulted in 30-50% better treatment results for specific disorders. Another study published in the Journal of Medical Internet Research discovered that AI-based precision medicine treatments reduced adverse events by 14% and hospital readmissions by 25%. These findings show AI's potential to improve treatment regimens, uncover successful medications, and save healthcare costs. Healthcare professionals may make more informed decisions by harnessing AI's analytical capacity and data-driven insights, resulting in better patient outcomes, increased treatment efficacy, and, ultimately, improved quality of care.

North America is the Market Leader in the AI in Precision Medicine Market.

North America has emerged as the market leader in AI in the precision medicine market. Several reasons contribute to the region's prominence. For starters, North America has a strong healthcare infrastructure and a high degree of technology innovation, which encourages the use of AI in precision medicine. Furthermore, the presence of top pharmaceutical and biotechnology businesses, research institutes, and academic centres in North America helps to the company's market leadership. Significant investments in AI research and development have occurred in the region, encouraging precision medical innovation. Furthermore, North America has a favourable regulatory framework and supporting policies that stimulate the use of artificial intelligence in healthcare. However, for the most up-to-date information on the leading region in the AI in precision medicine market, see the most recent market reports.

Integration of AI with Genomic Sequencing and Precision Medicine Enhances the AI in Precision Medicine Market Size.

In the healthcare business, the integration of AI with genome sequencing and precision medicine has become a crucial growth element. Genomic sequencing creates massive volumes of genetic data, which may then be analysed with AI algorithms to uncover disease-associated genetic variants and inform personalised treatment options. AI-powered genome analysis has yielded encouraging results, with studies claiming a 30% diagnosis yield in uncommon disorders. AI systems may also anticipate medication reactions based on genetic profiles, allowing for more tailored and effective therapy. The combination of AI with genomic sequencing has the potential to transform precision medicine by providing personalized treatments based on an individual's genetic composition, resulting in improved patient outcomes and treatment efficacy.

Key Developments:

  • In July 2023, Tempus, a pioneer in artificial intelligence and precision medicine, announced today a new collaboration to develop a companion diagnostic (CDx) test with TScan Therapeutics, a clinical-stage biopharmaceutical company focused on the development of TCR-engineered T cell therapies (TCR-T) for cancer patients. The partnership supports TScan's screening procedure for its Phase 1 solid tumour clinical trial, which is meant to allow patients to receive customised TCR-T mixes based on tumour antigen positivity and intact HLA expression.
  • In September 2021, Mila, the Quebec Artificial Intelligence Institute, announced today the beginning of a collaboration with Deep Genomics, a leader in therapeutic artificial intelligence therapies. This agreement will enable the firm to join Mila's network and take benefit of the research institute's recruitment operations. Deep Genomics employs artificial intelligence and machine learning to programme and choose revolutionary therapies for genetic illnesses with unmet medical needs.
  • In June 2023, Apptio Inc., a pioneer in financial and operational IT management and optimisation software, was purchased by IBM for $4.6 billion today in a formal deal with Vista Equity Partners. Apptio's purchase will accelerate IBM's IT automation capabilities and empower company executives to achieve greater business value from technology investments.

Company Products:

  • Genomic Sequencing: Tempus offers complete genome sequencing services, producing high-quality genetic data that may be combined with clinical data to reveal insights into disease development and therapy response.
  • Research Collaboration Program: 23andMe has worked with academic institutions and pharmaceutical businesses to collect vast amounts of genetic and phenotypic data for study. This massive dataset is analysed using AI, allowing researchers to unearth genetic insights and identify new treatment targets.
  • SOPHiA DDM Platform: SOPHiA GENETICS offers a comprehensive AI platform that analyses and interprets genetic data using machine learning and sophisticated algorithms. The platform aids in the identification of disease-causing variations, the prediction of therapy response, and the guidance of personalised treatment decisions.

Segmentation:

By Technology

  • Machine Learning
  • Natural Language Processing (Nlp)
  • Deep Learning
  • Big Data Analytics
  • Others

By Application

  • Drug Discovery And Development
  • Oncology
  • Genetic Testing
  • Rare Diseases
  • Infectious Diseases
  • Others

By End-User

  • Pharmaceutical And Biotechnology Companies
  • Research Institutes And Academic Centers
  • Healthcare Providers
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Taiwan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Sources
  • 2.3. Research Design

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. AI IN PRECISION MEDICINE MARKET, BY TECHNOLOGY

  • 5.1. Introduction
  • 5.2. Machine Learning
  • 5.3. Natural Language Processing (NLP)
  • 5.4. Deep Learning
  • 5.5. Big Data Analytics
  • 5.6. Others

6. AI IN PRECISION MEDICINE MARKET, BY APPLICATION

  • 6.1. Introduction
  • 6.2. Drug Discovery and Development
  • 6.3. Oncology
  • 6.4. Genetic Testing
  • 6.5. Rare Diseases
  • 6.6. Infectious Diseases
  • 6.7. Others

7. AI IN PRECISION MEDICINE MARKET, BY END-USER

  • 7.1. Introduction
  • 7.2. Pharmaceutical and Biotechnology Companies
  • 7.3. Research Institutes and Academic Centers
  • 7.4. Healthcare Providers
  • 7.5. Others

8. AI IN PRECISION MEDICINE MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Italy
    • 8.4.5. Spain
    • 8.4.6. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Taiwan
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

  • 10.1. IBM Corporation
  • 10.2. Google LLC (Alphabet Inc.)
  • 10.3. Microsoft Corporation
  • 10.4. Amazon Web Services (AWS)
  • 10.5. Intel Corporation
  • 10.6. NVIDIA Corporation
  • 10.7. Flatiron Health (Roche Holding AG)
  • 10.8. Tempus Labs, Inc.
  • 10.9. Foundation Medicine, Inc. (Roche Holding AG)
  • 10.10. 2bPrecise LLC (Allscripts Healthcare Solutions, Inc.)